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Summary
 
Stimulation of CD4
 
1
 
 helper T lymphocytes by antigen-presenting cells requires the degrada-
tion of exogenous antigens into antigenic peptides which associate with major histocompatibil-
ity complex (MHC) class II molecules in endosomal or lysosomal compartments. B lympho-
cytes mediate efficient antigen presentation first by capturing soluble antigens through clonally
distributed antigen receptors (BCRs), composed of membrane immunoglobulin (Ig) associated
 
with Ig-
 
a
 
/Ig-
 
b
 
 heterodimers which, second, target antigens to MHC class II–containing com-
partments. We report that antigen internalization and antigen targeting through the BCR or its
Ig-
 
a
 
–associated subunit to newly synthesized class II lead to the presentation of a large spec-
trum of T cell epitopes, including some cryptic T cell epitopes. To further characterize the in-
tracellular mechanisms of BCR-mediated antigen presentation, we used two complementary
experimental approaches: mutational analysis of the Ig-
 
a
 
 cytoplasmic tail, and overexpression
in B cells of dominant negative syk mutants. Thus, we found that the syk tyrosine kinase, an ef-
fector of the BCR signal transduction pathway, is involved in the presentation of peptide–
MHC class II complexes through antigen targeting by BCR subunits.
Key words: B cell receptor • syk tyrosine kinase • antigen presentation • major 
histocompatibility complex class II • immunoglobulin
 
A
 
ntigen-presenting cells (APCs), to stimulate CD4
 
1
 
helper T lymphocytes, must capture and process exog-
enous antigens into antigenic peptides which associate with
MHC class II molecules in the endocytic pathway (1, 2).
The formation of peptide–class II complexes classically oc-
curs in endolysosomal compartments (called MIIC or
CIIV), which accumulate newly synthesized class II mole-
cules (3–5), or in recycling endosomes, which contain ma-
ture class II molecules internalized from the cell surface and
then recycled back to the plasma membrane (6, 7). There-
fore, peptide–class II complexes may be generated at any
point throughout the endocytic pathway (8). This study
delineates how antigen receptors might determine the de-
livery of antigens to different compartments and thus could
modulate MHC class II–restricted antigen presentation.
 
B lymphocytes mediate efficient class II–restricted anti-
gen presentation first by facilitating the uptake of soluble
antigens through clonally distributed receptors (BCRs)
 
1
 
(9). These receptors are multichain complexes composed of
a ligand-binding module, the membrane immunoglobulin
(mIg), and a transducing module, the Ig-
 
a
 
/Ig-
 
b
 
 hetero-
dimer (10, 11), both chains containing a conserved peptidic
motif located in their cytoplasmic tails. This immunorecep-
tor tyrosine–based activation motif (ITAM [12, 13]) con-
sists of conserved amino acid residues (D2xY2xL7xY2xL)
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Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; GST, glu-
tathione 
 
S
 
-transferase; HA, hemagglutinin; HEL, hen egg lysozyme;
HRP, horseradish peroxidase; IC, immune complex(es); ITAM, immu-
noreceptor tyrosine–based activation motif; mIg, membrane immuno-
globulin; PI3 kinase, phosphatidylinositol 3-kinase; PTK, phospho-
tyrosine kinase; SH2, src homology 2 domain.
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which couple receptors to intracellular effectors, leading to
cell activation (11) and antigen internalization (14–16). An-
tigen recognition by mIg triggers the activation of Src fam-
ily phosphotyrosine kinases (PTKs), resulting in tyrosine
phosphorylation of Ig-
 
a
 
/Ig-
 
b
 
 ITAM (17) and the recruit-
ment of PTK Syk by phosphorylated ITAM (18, 19),
which turns on different signaling pathways (11). Concom-
itantly, the BCR facilitates the endocytosis of soluble anti-
gens and their access to endosomal/lysosomal compart-
ments, where the antigens are degraded into peptides
which then associate to MHC class II molecules to be pre-
sented to T lymphocytes (20). Therefore, another impor-
tant function of the BCR is to address soluble antigens to
the intracellular sites of peptide loading on class II mole-
cules (5, 15). To understand the role of the BCR in anti-
gen presentation, a critical question should therefore be ad-
dressed: Do signal transduction effectors, involved in
BCR-mediated B cell activation, determine the presenta-
tion of peptide–MHC class II complexes through BCR-
mediated antigen internalization?
The functions of BCR subunits in the intracellular tar-
geting of the BCR partially answer this question. Indeed,
the BCR is involved in the delivery of mIg-bound antigens
to newly synthesized MHC class II molecules accumulating
in endosomal compartments (5). The association of the Ig-
 
a
 
/Ig-
 
b
 
 sheath to mIg may account for the ability of the
BCR to induce both specific endosomal targeting and effi-
cient antigen presentation (14, 15). In the complex struc-
ture of the BCR, both Ig-
 
a
 
 and Ig-
 
b
 
 cytoplasmic domains
contain internalization signals (16), but only the Ig-
 
a
 
 cyto-
plasmic tail was able to target antigens to newly synthesized
MHC class II, whereas Ig-
 
b
 
 cytoplasmic tail contains tar-
geting signals that direct antigens towards recycling class II
(16). In addition, the cytoplasmic tails of Ig-
 
a
 
 and Ig-
 
b
 
were reported to interact with distinct cytoplasmic effectors
(21) and to trigger different signaling pathways (22). Thus,
the cytoplasmic domain of Ig-
 
a
 
 interacts with specific cy-
toplasmic proteins that might be necessary for the intracel-
lular targeting of the antigen-bound BCR to MHC class II
compartments. Two related questions were addressed spe-
cifically: Does BCR-mediated antigen targeting to class II
compartments have any immunological consequences for
the selection of specific T cell epitopes, and what are the
cytoplasmic effectors of this particular endosomal sorting of
antigen-bound BCR to class II compartments? We show
that the delivery of mIg-bound antigens, through Ig-
 
a
 
, to
newly synthesized MHC class II molecules induced the
presentation of a large spectrum of T cell epitopes derived
from 
 
l
 
 repressor (C1), hen egg lysozyme (HEL), or oval-
bumin (OVA). In contrast, antigen targeting to recycling
class II through the Ig-
 
b
 
 cytoplasmic tail led to the presen-
tation of only some of these epitopes. We then identified a
signal in the Ig-
 
a
 
 cytoplasmic tail that was responsible for
the presentation of these T cell epitopes and the activation
of syk tyrosine kinase. Endogenous syk activation and pre-
sentation of T cell epitopes, induced through the Ig-
 
a
 
 cyto-
plasmic tail, were abolished by the overexpression of a syk
mutant devoid of kinase domain, which had no effect on an-
tigen presentation induced by the Ig-
 
b
 
 cytoplasmic tail.
Therefore, the recruitment of syk tyrosine kinase by the Ig-
 
a
 
BCR subunit in the endosomal pathway may be an impor-
tant step in potentiating secondary B cell immune response
by addressing antigens to MHC class II compartments.
 
Materials and Methods
 
B Lymphoma Cell Lines.
 
The B lymphoma IIA1.6 is an
Fc
 
g
 
R-defective variant of A20 B lymphoma cells (23). The anti-
TNP A20 cells were obtained by transfection of genomic clones
encoding the light and the heavy 
 
m
 
 chains of the BCR specific
for TNP (24). These cell lines were cultured in RPMI 1640 con-
taining 10% FCS, 10 mM glutamine, 100 U/ml penicillin, 100
 
m
 
g/ml streptomycin, 50 
 
m
 
M 2-ME, and 5 mM sodium pyruvate
(GIBCO BRL, Paisley, UK). Fc
 
g
 
R/Ig-
 
a
 
 and Fc
 
g
 
R/Ig-
 
b
 
 chi-
meras were constructed by adding the DNA sequences encoding
the cytoplasmic domain of the Ig-
 
a
 
 or Ig-
 
b
 
 subunits to cDNA
encoding the extracellular and transmembrane domains of mouse
Fc
 
g
 
RII (22). cDNAs encoding Fc
 
g
 
R/Ig-
 
a
 
 chimeras with simple
or double mutations of tyrosine residues, contained in the ITAM,
were constructed using PCR with alanine in place of tyrosine. All
of these constructs have been described previously (25). The re-
sulting constructions were inserted in an expression vector bear-
ing a neomycin gene resistance, sequenced, and stably expressed
in the mouse B cell line IIA1.6. Cell surface expression of Fc
 
g
 
R
chimeras was measured with the rat anti–mouse Fc
 
g
 
R mAb
2.4G2, and was revealed by FITC-coupled mouse anti–rat anti-
bodies (26). The samples were analyzed with a FACScan
 
Ò
 
 flow
cytometer (Becton Dickinson, San Jose, CA).
 
Stable Expression of Syk Dominant Negative Mutant.
 
The syk dom-
inant negative mutant was constructed by joining the EcoRI-KpnI
fragment of rat syk cDNA (27) to a KpnI-XbaI PCR fragment
amplified from a hemagglutinin (HA)-tag–containing plasmid.
The sequence coding for the HA-tag is recognized by the mAb
12CA5. The resulting truncated syk has been sequenced, and
corresponded to the first 260 amino acids of the rat syk cDNA
fused to the sequence GSGYSYDVPDYA. This construct was
then inserted in an Sr-driven expression vector bearing the puro-
mycin gene resistance. After linearization with ScaI restriction
enzyme, 50 
 
m
 
g of DNA was used to electroporate B cells express-
ing Fc
 
g
 
R/Ig-
 
a
 
 or Fc
 
g
 
R/Ig-
 
b
 
 chimeras as described (26). After
48 h, the transfected cells were resuspended at 10
 
3
 
 cells/ml in a
culture medium containing 2 
 
m
 
g/ml puromycin (Sigma Chemi-
cal Co., St. Louis, MO). This cell suspension was distributed in
96-well plates at 100 
 
m
 
l/well and kept at 37
 
8
 
C for several weeks.
Growing cells were selected for the expression of the truncated
syk using FITC-coupled 12CA5 anti–HA-tag antibody (Boeh-
ringer Mannheim Corp., Indianapolis, IN). Cells were fixed with
3% paraformaldehyde in PBS, then incubated for 10 min in 100
mM glycine in PBS. Cells were permeabilized with 0.05% sapo-
nin (Sigma Chemical Co.) in PBS, then further incubated for 30
min at room temperature with 20 
 
m
 
g/ml FITC-coupled 12CA5
in 0.05% saponin, 0.2% BSA in PBS. After washing, the cells
were resuspended in PBS, and the samples were analyzed by
FACScan
 
Ò
 
 (Becton Dickinson). Positive cells were further char-
acterized by Western blotting using an affinity-purified rabbit an-
tibody raised against the amino acids 13–31, mapping in the first
src homology 2 (SH2) domain of the human syk (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). The sequence of this pep-
tide is identical in rat and mouse syk. 5 
 
3
 
 10
 
5
 
 cells were lysed
with 0.5% Triton X-100, then run on 10% polyacrylamide gels 
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Table 1.
 
Presentation of Different T Cell Epitopes after Antigen Internalization through BCR Ig-
 
a
 
 or Ig-
 
b
 
 Subunits
 
T cell hybridoma and epitopes Fc
 
g
 
R/Ig-
 
a
 
Fc
 
g
 
R/Ig-
 
b
 
Fc
 
g
 
R/Ig-
 
a
 
Y23-A
Fc
 
g
 
R/Ig-
 
a
 
Y34-A
Fc
 
g
 
R/Ig-
 
a
 
Y23-A Y34-A
 
l
 
 repressor
24.4 IA
 
d
 
 12-26
 
1111 1
 
26.1 IE
 
d
 
 12-26
 
1222 2
 
A128 IA
 
d
 
 48-64
 
11
 
ND ND ND
4G2 IA
 
d
 
 80-102
 
12
 
ND ND ND
HEL
B9.1 IE
 
d
 
 108-116
 
1 1 111 1
 
CAB43 IA
 
d
 
 44-62
 
1222 2
 
OVA
3DO 54.8 IA
 
d
 
11
 
ND ND ND
3DO 18.3 IA
 
d
 
12
 
ND ND ND
The data reported in this table summarize the results of five independent experiments for the C1 hybridomas and three experiments for the HEL and
OVA hybridomas.
 
1
 
, Increase (of at least 30-fold) in the efficiency of antigen presentation of IC compared with free antigen.
 
2
 
, A similar efficiency of antigen presentation of free antigen and IC.
and transferred onto polyvinylidene difluoride membranes (Milli-
pore Corp., Bedford, MA). The filters were incubated for 1 h
with 0.1 
 
m
 
g/ml of the anti-syk antibody, washed three times,
then further incubated with a horseradish peroxidase (HRP)-cou-
pled goat anti–rabbit antiserum (Amersham Pharmacia Biotech,
Inc., Piscataway, NJ). Chemiluminescence was detected using a
commercial kit (Boehringer Mannheim Corp.). The G2 and C2
clones for the Fc
 
gR/Ig-a–expressing cells, and the E8 and E10
clones for the FcgR/Ig-b–expressing cells were selected because
they expressed high levels of truncated syk (30 kD), and because
they expressed similar levels of FcgR chimera (detected with the
rat anti–mouse FcgR antibody 2.4G2) as parental cells.
T Cell Hybridomas. T cell hybridomas and cells used in anti-
gen presentation assays were cultured in RPMI 1640 containing
10% FCS, 10 mM glutamine, penicillin (100 U/ml), streptomy-
cin (100 mg/ml), and 2b-ME (5 3 1025 M). The specificity of all
CD41 T cell hybridomas is shown in Table 1. The C1 l repres-
sor–specific hybridomas 24.4, A128, 26.1, and 4G2 were charac-
terized previously (28–30). The anti-HEL T cell hybridomas
B9.1 and CAB43 and the anti-OVA T cell hybridomas 3DO
54.8 and 3DO18.3 were described previously (31, 32).
Assays for Antigen Presentation. Antigen presentation was as-
sessed by culturing transfected IIA1.6 cells together with specific
T cell hybridomas for 18–20 h in the presence of various concen-
trations of antigens complexed or not with specific antibodies.
The l repressor was complexed with the two mAbs 22D and 51F
(33), the HEL (Sigma Chemical Co.) was complexed with the
mAbs F10.6.14 and F9.13.7 (34), and the OVA was complexed
with the IgG fraction of a rabbit anti-OVA antiserum (Sigma
Chemical Co.). The complexes were preformed by incubating
different concentrations of purified l repressor, HEL, or OVA
(from 30,000 to 0.5 ng) with 15 mg/ml of each mAb or 50 mg/ml
of rabbit IgG at 378C for 15 min. The release of IL-2 by the T
cell hybridoma was determined by a CTL.L2 proliferation assay
(35). Each point represents the average of duplicate samples,
which varied by ,5%.
Kinetics analysis was performed as described previously (16). In
brief, a dose of antigen (3 mg/ml) was used for which antigen pre-
sentation was strictly dependent on immune complex (IC) forma-
tion with the mAbs. IC were preformed at 378C by mixing the
purified l repressor with 51F and 22D mAbs to make a 103 mix
in the culture medium. 30 ml of preformed IC was added to 270
ml of APCs adjusted to 2 3 106 cells/ml and incubated at 378C for
different times. To assess antigen presentation by A20 cells ex-
pressing TNP-specific IgM, TNP-coupled l repressor (10 TNP
per molecule of l repressor) were incubated under similar condi-
tions. The cells were then washed twice with PBS, fixed with
0.05% glutaraldehyde for 20 min on ice, and washed again twice.
Fixed cells in duplicate samples of 100 ml were added to 50 ml of
T cell hybridomas and adjusted to 2 3 106 cells/ml. After 24 h,
IL-2 production was tested as above. When indicated, APCs
were preincubated for 3 h at 378C with 10 mg/ml cycloheximide
diluted from a stock solution at 10 mg/ml in water. In this case,
cycloheximide was also present during incubation with pre-
formed IC before fixation with glutaraldehyde.
The binding of OVA IC to FcgRs was confirmed by
immunofluorescence and FACScanÒ analysis. The complexes
were made by mixing OVA (15 mg/ml; Sigma Chemical Co.)
and the IgG fraction of a rabbit anti-OVA antiserum (50 mg/ml;
Sigma Chemical Co.). For costimulation experiments, APCs
were incubated with or without OVA IC for 18 h and then fixed
as described above. Fixed cells in duplicate samples of 100 ml
were added to 50 ml of T cell hybridomas 24.4 and 26.1 (adjusted
to 2 3 106 cells/ml) and various concentrations of C1 l repressor
12–26 peptides. In another set of experiments, APCs were incu-
bated either with l repressor (30 mg/ml) and preformed OVA IC
to stimulate FcgR, or with preformed l repressor IC (as de-
scribed above) and F(ab9)2 fragments of specific goat anti–mouse
IgG2a antibodies (15 mg/ml; Southern Biotechnology Associates,
Inc., Birmingham, AL), which do not cross-react with IgG1 anti–l
repressor mAbs 51F and 22D, and specifically stimulate endog-
enous membrane IgG2a on IIA1.6 cells. After 18 h, the cells were822 Role of Syk Tyrosine Kinase in BCR-mediated Antigen Presentation
fixed and incubated with C1 l repressor–specific T cell hybrido-
mas 24.4 and 26.1. T cell stimulation was assessed using a
CTL.L2 proliferation assay.
Detection of Tyrosine Kinase Activation. Cells were preincubated
at 48C with or without 20 mg/ml of 2.4G2 for 30 min, and then
washed twice with RPMI 1640. 5 3 106 cells were then stimu-
lated with prewarmed F(ab9)2 fragments of mouse anti–rat antise-
rum (50 mg/ml) at 378C for 2 min. As a positive control, un-
treated cells were stimulated with prewarmed F(ab9)2 fragments of
anti-IgG antibodies (30 mg/ml) for 2 min at 378C. The stimu-
lated cells were washed and resuspended in lysis buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 0.5% Triton X-100) containing a
cocktail of protease inhibitors and tyrosine phosphatase inhibitors
(5 mM NaF, 5 mM EDTA, 1 mM Orthovanadate). Phosphopro-
teins were immunoprecipitated with agarose-coupled antiphos-
photyrosine antibodies PT-66 (Sigma Chemical Co.) or a rabbit
antiserum raised against the 11 COOH-terminal amino acids
from human syk coupled with KLH. The phosphoproteins were
then run on 10% SDS-PAGE gels and transferred onto polyvi-
nylidene difluoride membrane (Millipore Corp.) to be detected
with the antiphosphotyrosine mAb Py20 coupled with HRP
(ICN Biomedicals, Orsay, France). Chemiluminescence was de-
tected with a commercial kit (Boehringer Mannheim Corp.) by
exposure of the filters to X-omat film (Eastman Kodak Co.,
Rochester, NY). The filters were then stripped by a 30-min in-
cubation at 508C in 50 mM Tris, pH 6.8, 2% SDS, 100 mM
b-mercaptoethanol, incubated for 1 h with 0.1 mg/ml of the
anti-syk antibody (Santa Cruz Biotechnology, Inc.), washed three
times, then further incubated with an HRP-coupled goat anti–
rabbit antiserum. For the kinase assay, 1 mg of glutathione
S-transferase (GST)-HS1 fusion protein served as a specific sub-
strate for syk immunoprecipitated (36) in 30 ml of kinase buffer (30
mM Hepes, pH 7, 10 mM MgCl2, 5 mM MnCl2, 70 mM Ortho-
vanadate). It was constructed by joining a BamHI-EcoRI PCR
fragment containing the HSI peptide motif (EQEDEPEGDY-
EEVLE-Stop) in-frame into the polylinker of the pGEK-2TK
vector.
IC Internalization. The cells were washed once in internaliza-
tion buffer (RPMI 1640, 5% FCS, 10 mM glutamine, 5 mM so-
dium pyruvate, 50 mM 2-ME, and 20 mM Hepes, pH 7.4) and
incubated with HRP–anti-HRP IC for 2 h at 48C (107 cells/ml).
IC were prepared as a 103 solution in internalization buffer
(HRP 50 mg/ml, and a polyclonal rabbit anti-HRP antibody at
400 mg/ml) for 30 min at 378C. After fixation of HRP IC, the
cells were washed three times in internalization buffer and incu-
bated at 378C for various times (2 3 106 cells/ml). Internalization
was stopped by adding cold internalization buffer, and the cells
were washed once in PBS. Duplicates for each time point were
either left in PBS at 48C to measure cell surface HRP IC, or in-
cubated in Triton X-100 (0.1%) for 5 min at room temperature
to measure the total amount of HRP IC. The HRP was revealed
by adding substrate buffer (0.5 mg/ml OPD [Sigma Chemical
Co.] and 0.12% H2O2 in 0.05 M phospho-citrate buffer, pH 5.0)
at 48C. The reaction was stopped with 6 N HCl, and the change
in color was determined spectrophotometrically at 492 nm.
Results
BCR-mediated Antigen Uptake Induces the Presentation of
Numerous T Cell Epitopes. The binding of exogenous an-
tigens to the BCR potentiates antigen uptake and degrada-
tion in B lymphocytes. To determine if BCR-mediated
antigen uptake has any consequences for the presentation
of various T cell epitopes, we compared antigen presenta-
tion after fluid phase or BCR-mediated antigen uptake us-
ing A20 B cells expressing or not expressing TNP-specific
IgM. The l phage repressor (C1) was used as antigen.
TNP-coupled (3 mg/ml) or -uncoupled C1 (30 mg/ml)
was incubated for various times with A20 cells expressing
anti-TNP IgM (A20 anti-TNP). The cells were then fixed,
and C1 presentation was detected with two T hybridomas
specific for the same peptide in association with IA or IE of
the H2d haplotype: the hybridoma 24.4, which recognized
a dominant T cell epitope (IAd 12-26), and the hybridoma
26.1, which recognized a cryptic T cell epitope (IEd 12-26)
(28). These two T cell epitopes were detected on anti-
TNP A20 cells after 2 h of incubation with TNP-coupled
antigens (Fig. 1 a). The incubation of presenting cells with
the protein synthesis inhibitor cycloheximide for 3 h before
and during incubation with TNP-coupled C1 completely
abolished BCR-mediated antigen presentation (Fig. 1 a). In
contrast, fluid phase uptake of uncoupled C1 (Fig. 1 a) only
led to the presentation of the IAd 12-26 epitope after a lag
time of 4 h. Under these conditions, antigen presentation
was partially resistant to the cycloheximide treatment.
Therefore, BCR-mediated antigen internalization has a
dual function in antigen presentation: by addressing anti-
gens to newly synthesized MHC class II molecules, BCR
induces the presentation of T cell epitopes which are not
presented after fluid phase antigen uptake.
The cytoplasmic tail of the BCR Ig-a subunit is able to
target antigen to newly synthesized MHC class II (16).
Therefore, we investigated whether the direct targeting of
C1 through the cytoplasmic tail of Ig-a is able to induce
the presentation of the dominant, IAd 12-26, and the cryp-
tic, IEd 12-26, T cell epitopes. IIA1.6 B cells (FcgR-defec-
tive variant of A20 B cells) expressing FcgR chimeras con-
taining the cytoplasmic tail of Ig-a or Ig-b (FcgR/Ig-a
and FcgR/Ig-b, respectively [22]) were incubated with C1
(3 mg/ml) complexed with two anti-C1 mAbs (15 mg/ml
each) to target C1 on FcgR chimeras. After various periods
of culturing at 378C, the presenting cells were fixed and in-
cubated with the two T cell hybridomas 24.4 and 26.1.
The presentation of IAd 12-26 and IEd 12-26 T cell epitopes
occurred with similar kinetics on FcgR/Ig-a–expressing
cells (Fig. 1 b) and A20 anti-TNP (Fig. 1 a). In addition,
the incubation of presenting cells with cycloheximide in-
hibited antigen presentation induced by direct targeting of
C1 through the Ig-a cytoplasmic tail (Fig. 1 b). Surpris-
ingly, similar experiments with FcgR/Ig-b–expressing cells
revealed that endosomal targeting of C1 to recycling class
II by the Ig-b cytoplasmic tail (16) was not able to induce
presentation of the cryptic IEd 12-26 T cell epitope,
whereas the dominant IAd 12-26 T cell epitope was effi-
ciently and quickly presented by recycling class II mole-
cules (no effect of cycloheximide treatment; Fig. 1 b).
Using HRP–anti-HRP rabbit IgG IC as a multivalent
ligand of FcR chimeras, we observed that both Ig-a and
Ig-b chimeras internalized IC with similar efficiency and
kinetics (Fig. 1 c). Therefore, the incapacity of the Ig-b823 Lankar et al.
chimera to induce presentation of the IEd 12-26 epitope
was not due to inefficient ligand internalization. These re-
sults suggested that the BCR induced presentation of a
dominant and a cryptic T cell epitope by newly synthesized
class II molecules through a targeting signal contained in
the cytoplasmic tail of Ig-a.
Therefore, a function of the BCR in antigen presenta-
tion might be to induce the presentation of a large spec-
trum of T cell epitopes by targeting antigens to newly syn-
thesized class II. To address this question, we used a panel
of T cell hybridomas specific for various peptides deriving
from C1, HEL, or OVA, restricted by the IA or IE H2d
class II molecules. The efficiency of presentation of IgG-
complexed antigens was compared in FcgR/Ig-a– and
FcgR/Ig-b–expressing cells (Table 1). The targeting of
these different proteins through the cytoplasmic tail of Ig-a
induced the presentation of all epitopes tested, i.e., C1 IAd
48-64 and IAd 80-102, HEL IEd 108-116 and IAd 44-62,
and the IAd-restricted OVA epitopes recognized by the
3DO54.8 and the 3DO18.3 T cell hybridomas. In contrast,
the processing of the same IC by FcgR/Ig-b–expressing
cells led only to the presentation of some of these T cell
epitopes (Table 1). Antigen targeting by the Ig-a or Ig-b
cytoplasmic tails through newly synthesized or recycling
class II molecules, respectively, did not lead to the presenta-
tion of the same peptides. These results raised the question,
What is the intracellular mechanism of specific presentation
of these T cell epitopes by Ig-a and BCR-mediated antigen
internalization?
B Cell Activation Is Not Sufficient for Presentation of the
Cryptic Epitope. The Ig-a and Ig-b cytoplasmic tails in-
duce the activation of different signaling pathways (22) and
interact with distinct cytoplasmic effectors (21). Therefore,
the selective presentation of epitopes by B cells expressing
anti-TNP–specific IgM or FcgR/Ig-a chimera might be
either a direct consequence of a different intracellular tar-
geting of antigen, or an indirect effect of B cell activation
which might induce surface expression of putative costim-
ulatory molecules required for the efficient activation of T
cell hybridomas.
To distinguish between these possibilities, the FcgR/
Ig-a– and FcgR/Ig-b–expressing cells were incubated with
or without irrelevant IC (OVA, 15 mg/ml; anti-OVA rab-
bit IgG, 50 mg/ml), to induce B cell activation (not
shown). After 24 h, the cells were then fixed and incubated
with increasing concentrations of 12-26 peptide and either
the 24.4 or the 26.1 T cell hybridoma. The peptide was
presented to both T cells with similar efficiency by the un-
stimulated and the stimulated cells (Fig. 2 a). Similar results
were obtained when the cells were fixed after 6 or 12 h in-
cubation with IC (not shown). Therefore, the signaling
pathways induced through Ig-a and Ig-b did not modify
the efficiency of presentation of the 12-26 peptide by IAd
and IEd molecules.
Nevertheless, the BCR or Ig-a cytoplasmic tail could
induce signaling events that modified the composition of
processing compartments, leading to the presentation of the
IEd 12-26 epitope. The effect of Ig-a–induced cell activa-
tion on intracellular processing of C1 was assessed by coin-
cubating FcgR/Ig-a–expressing cells with irrelevant IC (as
shown in Fig. 2 a) in order to trigger cell activation
through the Ig-a cytoplasmic tail, and with soluble C1 (30
mg/ml), which typically only induced the presentation of
the IAd 12-26 epitope (see Fig. 1 a and Fig. 3 b). After 24 h,
the cells were fixed and incubated either with 24.4 or 26.1
T cells (Fig. 2 b). B cell signaling through Ig-a did not lead
to the presentation of the IEd 12-26 epitope and did not in-
Figure 1. The BCR and BCR Ig-a subunit determined antigen pre-
sentation by newly synthesized class II molecules. (a) A20 cells expressing
anti-TNP–specific mIg were incubated with TNP-coupled (top, circles) or
uncoupled (bottom, squares) l repressor (3 and 30 mg/ml, respectively) for
various times with (1) or without (2) cycloheximide (Cx; 10 mg/ml).
The cells were then fixed with glutaraldehyde before incubation with the
T cell hybridoma 24.4, specific for the IAd 12-26 dominant epitope, or with
the T cell hybridoma 26.1, specific for the IEd 12-26 cryptic epitope. (b)
IIA1.6 cells expressing either FcgR/Ig-a (top) or FcgR/Ig-b chimera
(bottom) were incubated with C1 l repressor–IgG complexes for various
times with (1) or without (2) cycloheximide (Cx; 10 mg/ml). The cells
were then fixed with glutaraldehyde before incubation with the same two
T cell hybridomas for 24 h. T cell stimulation was evaluated by a CTL.L2
proliferation assay. Similar results were obtained in three independent ex-
periments. (c) Internalization of the HRP–anti-HRP IC by FcgR/Ig-a or
FcgR/Ig-b chimera was measured as described in Materials and Methods.824 Role of Syk Tyrosine Kinase in BCR-mediated Antigen Presentation
crease the presentation of the IAd 12-26 epitope after the
fluid phase uptake of the C1 (Fig. 2 b).
However, fluid phase antigen uptake is not very efficient
in B cells, and could be a limiting step that leads to failure
to generate enough peptides to induce the presentation of
the IEd 12-26 epitope. To test this possibility, the FcgR/
Ig-b–expressing cells were simultaneously incubated with
IgG1-complexed C1 (to allow efficient generation of 12-26
peptide) and with specific anti-IgG2a antibodies (to induce
B cell activation through endogenous mIg). The cells were
then fixed and incubated with the two T cell hybridomas.
BCR stimulation did not induce FcgR/Ig-b–expressing
cells to present IEd 12-26 epitope and did not increase pre-
sentation of the IAd 12-26 epitope (Fig. 2 c). Therefore, the
stimulation of the whole BCR was not sufficient to allow
presentation of the cryptic IEd 12-26 epitope after C1 in-
ternalization through the Ig-b cytoplasmic tail; however,
the 12-26 peptide was efficiently generated since it was
presented by IAd molecules, although the direct targeting
of C1 to the TNP-specific BCR was able to induce pre-
sentation of the same T cell epitope (Fig. 1 a). In addition,
the failure of the Ig-b chimera to induce presentation of
cryptic IEd 12-26 epitope was not due to a lower sensitivity
of the T cell hybridoma, as suggested by the results ob-
tained for fixed presenting cells (shown in Fig. 2 a), since
similar results were obtained with unfixed cells (Table 1).
Indeed, on unfixed cells, the two T cell hybridomas de-
tected the IAd 12-26 and IEd 12-26 T cell epitopes with
similar sensitivity (see Fig. 3 c, and data not shown). These
data suggested that the BCR Ig-a subunit contains a signal
that can recruit proteins involved in the antigen targeting
toward endosomal compartments, where the 12-26 peptide
may be generated and associated to IAd and IEd MHC class
II molecules.
Tyrosine Residues Contained in the Ig-a Cytoplasmic Tail
Are Required for Receptor-mediated Presentation of the Cryptic
IEd 12-26 T Cell Epitope. The two major functions as-
signed to the Ig-a/Ig-b heterodimer are intracellular sig-
naling and receptor internalization, both dependent on
ITAMs contained in their cytoplasmic tails. To discrimi-
nate between these two functions of the BCR subunits, we
analyzed antigen presentation through FcgR/Ig-a chime-
ras containing mutated tyrosine residues, previously shown
to prevent the activation of tyrosine kinases (25).
First, we analyzed IC internalization by the FcgR/Ig-a
chimera in which tyrosine residues of Ig-a ITAM were re-
placed by alanines (FcgR/Ig-a Y23-A Y34-A). HRP–
anti-HRP rabbit IgG IC were bound to wild-type and mu-
tated FcgR/Ig-a–expressing cells at 48C, then the cells
were cultured at 378C for various times to allow receptor
internalization. Internal and cell surface fractions of IC
were determined by an enzymological assay. As shown in
Fig. 3 a, both wild-type and mutated Ig-a chimeras inter-
nalized IC with similar kinetics. Tyrosine residues of Ig-a
ITAM, as for Ig-b (37), did not appear to be required for
the internalization of multivalent ligands.
Therefore, we evaluated whether mutation of these ty-
rosine residues, which inhibit B cell activation, altered the
presentation of the dominant, IAd 12-26, and the cryptic,
IEd 12-26, T cell epitopes. Cells were incubated with vari-
ous concentrations of C1 complexed or not with two anti-
C1 mAbs (15 mg/ml each) and the two T cell hybridomas.
Although wild-type and double-mutated FcgR/Ig-a chi-
meras were able to induce presentation of the IAd 12-26
epitope at low concentrations of IgG-complexed C1, no
presentation of the cryptic IEd 12-26 epitope was detected
when IC were internalized through the FcgR/Ig-a Y23-A
Y34-A chimera (Fig. 3 b). We verified that stimulation of
the 24.4 and 26.1 T cell hybridomas was obtained at similar
Figure 2. B cell activation per se does not induce presentation of the
IEd-restricted epitope. (a) FcgR/Ig-a and FcgR/Ig-b chimera–express-
ing cells were incubated for 24 h with OVA–anti-OVA IC. The cells
were then fixed with glutaraldehyde and incubated at increasing concen-
trations of 12-26 C1 l repressor peptide and the T cell hybridomas spe-
cific for the dominant (IAd 12-26) or cryptic (IEd 12-26) epitopes. The
secretion of IL-2 in the cell culture supernatants was measured. Activation
of chimera-expressing cells with IC did not modify the efficiency of pre-
sentation of the 12-26 peptide. Similar results were obtained in two inde-
pendent experiments. (b) Cell activation through FcgR/Ig-a chimera
does not induce presentation of the cryptic epitope after antigen internal-
ization by fluid phase uptake. FcgR/Ig-a–expressing cells were incubated
overnight in the presence of 30 mg/ml C1 l repressor with or without
irrelevant OVA–anti-OVA IC, in order to engage FcgR/Ig-a chimeric
receptors. The cells were then fixed and reincubated overnight with T
cell hybridomas specific for the dominant or the cryptic epitopes. Engage-
ment of FcgR/Ig-a chimeric receptors did not induce presentation of the
IEd-restricted cryptic epitope. (c) Cell activation through surface IgG does
not induce the presentation of the C1 l repressor cryptic epitope after IC
internalization through FcgR/Ig-b. Cells expressing FcgR/Ig-b were in-
cubated continuously in the presence of C1 l repressor IC in the absence
or presence of specific goat anti–mouse IgG2a F(ab9)2 fragments, in order
to induce cell activation through endogenous surface IgG2a. The cells
were then fixed and reincubated overnight with T cell hybridomas spe-
cific for the dominant or the cryptic epitopes. Cell activation through sur-
face IgG2a did not induce presentation of the cryptic epitope by FcgR/
Ig-b –expressing cells. Errors bars in b and c indicate the mean variation of
T cell stimulation of three experiments.825 Lankar et al.
concentrations of 12-26 peptides with FcgR/Ig-a– or
FcgR/Ig-a Y23-A Y34-A–expressing cells (Fig. 3 c). In
addition, we obtained similar results with B cells expressing
Ig-a chimera where the first (FcgR/Ig-a Y23-A) or the
second (FcgR/Ig-a Y34-A) tyrosine residue of Ig-a
ITAM was mutated to alanine (Table 1). The mutation of
tyrosine residues of the Ig-a ITAM also affected the pre-
sentation of IAd 48-62 HEL epitopes, but had no effect on
the IEd 108-116 T cell epitope derived from HEL when
the antigen was complexed with specific antibodies (Table
1). Therefore, we concluded that mutations that abolished
the ability of the Ig-a cytoplasmic tail to induce B cell acti-
vation also blocked the intracellular targeting of antigens,
determining the presentation of some, but not all, T cell
epitopes.
The Recruitment of Syk Tyrosine Kinase Is Required for BCR-
mediated Antigen Presentation. After BCR stimulation, tyro-
sine kinases phosphorylate ITAM tyrosine residues, enabling
them to associate with the two SH2 domains of syk tyrosine
kinase (18, 19). Since mutation of the tyrosine of Ig-a
ITAM inhibits the generation of some T cell epitopes, we
further evaluated the role of syk tyrosine kinase in antigen
presentation through the BCR Ig-a subunit.
First, we tested whether the double mutation of both ty-
rosine residues contained in Ig-a ITAM affected syk acti-
vation through the cytoplasmic tail of Ig-a. Wild-type and
mutated FcgR/Ig-a–expressing cells were stimulated for
2 min at 378C through FcgRs (using the anti-FcgR mAb,
2.4G2), or through endogenous mIgG2a (using F(ab9)2
fragments of rabbit anti–mouse IgG), or, in a control ex-
periment, with irrelevant F(ab9)2 fragments of mouse anti–
rat IgG. Cell lysates were prepared, and phosphotyrosine
proteins were immunoprecipitated with agarose-coupled
PT66 and analyzed by immunoblotting with HRP-cou-
pled antiphosphotyrosine mAb Py20 or rabbit anti-syk
antisera. As shown in Fig. 4 a, B cell stimulation through
endogenous BCR or the Ig-a chimera induced the phos-
phorylation of similar proteins, among them the syk ty-
rosine kinase (Fig. 4 b). Mutated Ig-a chimera lacked the
ability to induce phosphorylation of syk as well as of other
kinases substrates, although endogenous mIgs were func-
tional in these cells (Fig. 4). In addition, the kinase activity
of syk was increased after FcgR/Ig-a stimulation but not
after cross-linking of the tyrosine-mutated Ig-a chimera as
measured by phosphorylation of a specific substrate of syk
kinase, a GST fusion protein containing HS1 polypeptide
(reference 36; Fig. 4 b). Therefore, the Ig-a cytoplasmic
tail is able to activate syk tyrosine kinase and to mediate the
presentation of numerous T cell epitopes via a targeting
signal located in the Ig-a ITAM.
To further evaluate the role of syk tyrosine kinase in an-
tigen presentation by B cells, we devised a strategy to spe-
cifically block the recruitment and activation of syk by the
Ig-a subunit of the BCR. For this purpose, an inactive
form of syk was stably expressed in FcgR/Ig-a–expressing
B cells. A cDNA encoding the two SH2 domains of syk
tagged with an HA peptide but lacking its kinase domain
was inserted in an expression vector bearing the puromycin
resistance gene. After transfection, expressing cells were se-
lected with puromycin and cloned. The clones were
screened for the expression of HA-tag by intracellular
FACScanÒ analysis using FITC-coupled anti-HA mAb
Figure 3. Tyrosine residues of Ig-a ITAM are involved in the selective
presentation of a cryptic epitope. (a) Internalization of the HRP–anti-
HRP IC by FcgR/Ig-a chimera or FcgR/Ig-a Y23A Y34A mutant was
measured as described in Materials and Methods. (b) IIA1.6 cells express-
ing either FcgR/Ig-a chimera or FcgR/Ig-a Y23A Y34A mutant were
cultured in the presence of increasing concentrations of C1 l repressor
(fluid phase uptake, squares) or C1 l repressor–IgG complexes (FcgR-
mediated endocytosis, circles). T cell hybridomas specific for a dominant
epitope (IAd 12-26) or a cryptic epitope (IEd 12-26) from the C1 l re-
pressor were also included in the cultures. The secretion of IL-2 by the T
cell hybrids was measured after an overnight incubation. (c) Both trans-
fected cell lines presented the 12-26 peptide on IAd or IEd with identical
efficiency. The data presented are representative of results obtained in
three independent experiments.826 Role of Syk Tyrosine Kinase in BCR-mediated Antigen Presentation
(not shown). Positive clones were further characterized by
Western blotting using a rabbit antiserum specific for a
peptide contained in the NH2 portion of the syk SH2 do-
mains present both in dominant negative mutant (32 kD)
and in endogenous syk (70 kD; Fig. 5 a). The activation of
endogenous syk kinase through the Ig-a cytoplasmic tail
was then analyzed in the A2 and G2 clones.
For this purpose, the two clones were left unstimulated
or stimulated through the Ig-a chimera or endogenous
mIgG2a, then phosphoproteins were immunoprecipitated
and analyzed by Western blotting using Py20 and anti-syk
antibodies. Overexpression of the syk dominant negative
mutant prevented the phosphorylation of various intracel-
lular proteins, as well as endogenous syk kinase, induced
Figure 4. Tyrosine residues of Ig-a ITAM are required for activation
of the syk tyrosine kinase through the BCR. IIA1.6 cells expressing either
FcgR/Ig-a chimera or FcgR/Ig-a Y23A Y34A mutant were left un-
stimulated or stimulated through endogenous BCR with F(ab9)2 frag-
ments of rabbit anti–mouse IgG antibodies (15 mg/ml), or through Fc
chimera with the rat anti–mouse FcgR antibody 2.4G2 (20 mg/ml) then
F(ab9)2 fragments of mouse anti–rat IgG (30 mg/ml). In control lanes, the
cells were incubated for the same time with only F(ab9)2 fragments of
mouse anti–rat IgG (30 mg/ml). The cells were then washed and lysed
with 0.5% Triton X-100. Cell lysates were immunoprecipitated with an-
tiphosphotyrosine antibodies (a) or rabbit anti-syk antibodies (b). (a)
Phosphoproteins were detected by Western blotting using HRP-coupled
antiphosphotyrosine antibody Py20 (top), or a rabbit antiserum specific for
the NH2-terminal end of the syk tyrosine kinase (bottom). (b) The phos-
phorylation of syk in immunoprecipitates was detected by Western blot-
ting using HRP-coupled antiphosphotyrosine antibody Py20 (top). The
syk tyrosine kinase activity was measured in a kinase assay using a specific
substrate, the GST–HS1 fusion proteins. The phosphorylation of GST–
HS1 fusion proteins was detected by Western blotting using HRP-cou-
pled antiphosphotyrosine antibody Py20 (middle). The rate of immuno-
precipitated syk tyrosine kinase was controlled for each point on the same
filter using a rabbit antiserum specific for the NH2-terminal end of the syk
tyrosine kinase (bottom).
Figure 5. A dominant negative mutant of syk inhibits the activation of
endogenous syk tyrosine kinase through the BCR Ig-a subunit. (a) A
cDNA encoding the two SH2 domains of the rat syk tyrosine kinase was
stably overexpressed in FcgR/Ig-a chimera cells. The clones G2 and C2
are representative of a series of 20 independent clones characterized by
Western blotting using a rabbit antiserum specific for the NH2-terminal
end of syk. Arrowheads, Endogenous syk tyrosine kinase (70 kD) and the
dominant negative mutant (32 kD). FcgR/Ig-a–positive cells overex-
pressing or not the dominant negative syk (G2 and C2 clones) mutant
were left unstimulated or stimulated through the endogenous BCR or Fc
chimera as described in the legend to Fig. 4. The cells were then washed
and lysed with 0.5% Triton X-100. Cell lysates were immunoprecipitated
with antiphosphotyrosine antibodies (b) or rabbit anti-syk antibodies (c).
(b) Phosphoproteins (top) or syk tyrosine kinase (bottom) was detected by
Western blotting as in Fig. 4. (c) The phosphorylation of GST–HS1 fu-
sion proteins was detected, after a kinase assay, by Western blotting using
HRP-coupled antiphosphotyrosine antibody Py20 (top). The quantity of
immunoprecipitated syk was controlled for each point on the same filter
using a rabbit antiserum specific for the NH2-terminal end of syk (bottom).827 Lankar et al.
through the Ig-a cytoplasmic tail. Although global tyrosine
phosphorylation was affected, syk phosphorylation was
only marginally decreased after B cell stimulation through
endogenous mIg (Fig. 5 b). Similarly, we found that over-
expression of syk SH2 domains led to a substantial inhibi-
tion of kinase activity in syk immunoprecipitates obtained
after cell stimulation through the Ig-a cytoplasmic tail,
whereas only a marginal effect was found after endogenous
mIg stimulation, although the same quantity of syk protein
was immunoprecipitated (Fig. 5 c). These results suggested
that syk could be activated through an Ig-a–dependent and
–independent pathway.
To verify this hypothesis, we examined the effect of
overexpression of syk dominant negative mutant on syk
activation through the cytoplasmic tail of Ig-b. Clones
overexpressing the syk dominant negative mutant were
obtained in B cells expressing the FcgR/Ig-b chimera. The
E8 and E10 clones, shown in Fig. 6 a, were analyzed. Syk
kinase activity and phosphorylation could not be inhibited
by overexpression of syk SH2 domains after stimulation of
the Ig-b chimera (Fig. 6 b). In conclusion, both subunits
of the Ig-a/Ig-b heterodimer were able to activate syk
tyrosine kinase, but only syk activation through Ig-a was
inhibited by the syk dominant negative mutant. This model
allowed us to evaluate the role of syk kinase in MHC class
II–restricted antigen presentation through the subunits of
the BCR.
Using HRP–anti-HRP rabbit IgG IC, we first estab-
lished that the overexpression of the syk dominant negative
mutant did not affect the internalization of cross-linked Ig-a
chimera (Fig. 7 a) or Ig-b chimera (not shown). The pre-
sentation of C1 was next analyzed in cells overexpressing
the syk dominant negative mutant. No presentation of the
cryptic IEd 12-26 epitope was detected when IC were in-
ternalized through the FcgR/Ig-a chimera in cells overex-
pressing the two syk SH2 domains, whereas presentation of
the dominant IAd 12-26 epitope was only slightly reduced
(Fig. 7 b). No effect of the syk dominant negative mutant
was observed with FcgR/Ig-b–expressing cells (Fig. 7 b),
although the cells stimulated the 24.4 and 26.1 T cell hy-
bridomas at similar concentrations of 12-26 peptide (Fig. 7
Figure 6. The syk dominant negative mutant did not affect endoge-
nous syk activation of endogenous syk tyrosine kinase through the BCR
Ig-b subunit. (a) A cDNA encoding the two syk SH2 domains was stably
overexpressed in FcgR/Ig-b chimera–positive cells. The E8 and E10
clones are representative of a series of 10 independent clones characterized
by Western blotting using a rabbit antiserum specific for the NH2-termi-
nal end of syk. Arrowheads, Endogenous syk tyrosine kinase (70 kD) and
the dominant negative mutant (32 kD). (b) FcgR/Ig-b–positive cells
overexpressing the dominant negative syk (E8 and E10 clones) mutant
were left unstimulated or stimulated through the endogenous BCR or Fc
chimera as in the legend to Fig. 4. The cells were then washed and lysed
with 0.5% Triton X-100. Cell lysates were immunoprecipitated with rab-
bit anti-syk antibodies (top; the kinase activity was measured and con-
trolled as in the legend to Fig. 4) or with antiphosphotyrosine antibodies
(bottom; phosphorylated syk was blotted with an anti-syk antiserum as in
the legend to Fig. 4).
Figure 7. Overexpression of syk dominant negative mutant selectively
affected presentation of the cryptic T cell epitope through the BCR Ig-a
subunit. (a) Internalization of the HRP–anti-HRP IC by the FcgR/Ig-a
chimera was measured in G2 (gray circles) and C2 (black circles) clones over-
expressing the syk dominant negative mutant. (b) FcgR/Ig-a (circles) and
FcgR/Ig-b (squares) chimera–positive cells overexpressing (black and gray)
or not (white) syk dominant negative mutant were cultured in the pres-
ence of increasing concentrations of C1–IgG complexes (FcgR-mediated
endocytosis). T cell hybridomas specific for a dominant epitope (IAd 12-
26) or a cryptic epitope (IEd 12-26) from the C1 l repressor were also in-
cluded in the cultures. The secretion of IL-2 by the T cell hybrids was
measured after an overnight incubation. (c) All the transfected cell lines
presented the 12-26 peptide on IAd or IEd with identical efficiency. (d)
The FcgR/Ig-a–positive presenting cells, overexpressing (black and gray)
or not (white) syk dominant negative mutant, were incubated with C1–
IgG complexes for various times, then fixed with glutaraldehyde before
incubation with the IAd 12-26–specific T cell hybridomas for 24 h. T cell
stimulation was evaluated by a CTL.L2 proliferation assay. Similar results
were obtained in three independent experiments.828 Role of Syk Tyrosine Kinase in BCR-mediated Antigen Presentation
c). In addition, overexpression of the syk dominant nega-
tive mutant slowed down presentation of the IAd 12-26
epitope after the internalization of IgG-complexed C1
through the Ig-a chimera (Fig. 7 d). Therefore, the over-
expression of the syk dominant negative mutant seemed
able to modulate the presentation of T cell epitopes which
are specifically generated by antigen targeting to newly
synthesized, such as the cryptic IEd 12-26, T epitope issu-
ing from the C1. The syk tyrosine kinase, a major effector
of the BCR-induced signaling pathway, therefore, is also
involved in BCR-mediated antigen presentation by newly
synthesized MHC class II molecules.
Discussion
Capture of antigens by BCRs is the first step in antigen
entry into the endosomal pathway, where antigenic pep-
tides are generated and associated with newly synthesized
MHC class II molecules. We report here that antigen tar-
geting to newly synthesized class II molecules through the
BCR or Ig-a–associated subunit induces the presentation
of a larger spectrum of T cell epitopes than antigen target-
ing to recycling class II molecules. Using mutagenesis anal-
ysis of the Ig-a cytoplasmic tail and stable overexpression
in B cells of a syk dominant negative mutant, we describe
evidence that signal transduction effectors of B lymphocyte
activation are involved in the generation of peptide–MHC
class II complexes.
How do Ig-a and Ig-b cytoplasmic tails induce presen-
tation of different T cell epitopes? Quantitative differences
in the rate of antigen internalization can be excluded, since
the Ig-a chimera was expressed at a lower level than the
Ig-b chimera (22), and since both chimeric receptors medi-
ated internalization of IC with similar kinetics and effi-
ciency (Fig. 1 c [16]). In contrast, the kinetics of antigen
presentation induced by the Ig-a and Ig-b cytoplasmic tails
demonstrated that they target antigens to newly synthesized
or recycling pools of MHC class II molecules, respectively.
Analysis of various T cell epitopes provides new evidence
to further distinguish these two antigen-presentation path-
ways. Thus, antigen internalization via the Ig-a, but not
the Ig-b, chimera stimulated the DO18.3 hybridoma (Ta-
ble 1), which recognizes an IAd-restricted OVA T cell
epitope specifically generated in invariant chain–positive
presenting cells (32, 38). In contrast, the invariant chain–
independent epitope recognized by DO54.8 hybridoma
(32) is presented after antigen internalization through the
Ig-a or Ig-b chimera. These data suggest that the Ig-a cy-
toplasmic tail targets antigens to endosomal compartments,
where class II molecules transiently accumulate through an
invariant chain–dependent mechanism which characterizes
newly synthesized class II molecules. In addition, the data
also supported the hypothesis that some T cell epitopes
cannot be generated in an alternative antigen-presentation
pathway defined by compartments where class II molecules
cycle with the cell surface (6, 7). Indeed, antigen targeting
to recycling class II molecules through Ig-b did not induce
the stimulation of DO18.3 hybridoma or other T cell hy-
bridomas specific for cryptic or subdominant epitopes de-
rived from the l repressor and HEL. Therefore, the two
MHC class II–restricted antigen pathways can be function-
ally distinguished on the basis of T cell epitopes they are
able to efficiently generate. However, the complete BCR
as well as the Ig-a chimera address antigen to the newly
synthesized pool of MHC class II molecules, presenting a
large spectrum of peptides. Therefore, the Ig-a subunit is
dominant over Ig-b in this process and accounts for the
ability of the BCR to induce efficient antigen presentation
during secondary in vivo immune responses. This conclu-
sion raised a new question: What is the intracellular mech-
anism of BCR- or Ig-a–mediated antigen presentation?
Two distinct functions have been assigned to Ig-a and
Ig-b: first, to address antigen to different pools of MHC
class II molecules (16), and second, to induce different sig-
naling pathways (22, 25). Therefore, the overall cell activa-
tion induced by Ig-a or the complete BCR might be re-
sponsible for the ability of the Ig-a chimera to induce
stimulation of numerous T cells. However, this hypothesis
is unlikely because, first, the stimulation of 12-26 IAd– and
IEd–restricted T cell hybridomas by Ig-a chimera–express-
ing cells was not modified by chimera cross-linking, and
second, the overall cell activation induced by BCR cross-
linking was not able to increase presentation of the IAd 12-26
epitope or to induce presentation of the IEd 12-26 epitope
by Ig-b chimera–expressing cells. These data indicated that
potential alterations in antigen processing during cell acti-
vation do not account for induction of presentation of
these T cell epitopes. In addition, we excluded the possibil-
ity that BCR or Ig-a chimera cross-linking increased cell
surface expression of MHC class II or costimulatory mole-
cules such as B.7 or CD40 ligand (not shown). In contrast,
mutagenesis analysis identifies, in the Ig-a cytoplasmic tail,
a targeting signal able to induce efficient antigen presenta-
tion of numerous peptides. Indeed, mutation of tyrosine
residues contained in the Ig-a ITAM, which completely
abolish signal transduction (25, 39, 40), affects Ig-a–medi-
ated antigen presentation, whereas similar mutation in Ig-b
ITAM did not affect BCR internalization and BCR-medi-
ated antigen presentation (37). These results indicate that
tyrosine residues of Ig-b and Ig-a ITAM are differently in-
volved in the recruitment of cytoplasmic effectors mediat-
ing antigen presentation.
Tyrosine mutants of the Ig-a ITAM also provide a new
tool to dissociate the two major functions of the BCR,
ligand internalization and signal transduction, since these
mutations block activation of most of the tyrosine kinases
but had no effect on receptor internalization. In addition,
these mutations specifically alter the presentation of some,
but not all, T cell epitopes and inhibited the phosphoryla-
tion and activation of syk tyrosine kinase. The role of the
kinase activity of syk in BCR-mediated antigen presenta-
tion was investigated using B cells overexpressing the two
SH2 domains of syk. This mutant protein may be recruited
by tyrosine-phosphorylated ITAM and should act as a
dominant negative mutant of ITAM function. Indeed, in
cells overexpressing the syk mutant, the activation of en-829 Lankar et al.
dogenous syk kinase was blocked after Ig-a chimera stimu-
lation and was inhibited after BCR stimulation, whereas
syk activation through Ig-b was not affected by overex-
pression of the syk mutant. It is probable that the ITAMs of
both BCR subunits activated syk by different mechanisms
as suggested by previous data indicating that the Ig-a and
Ig-b cytoplasmic tails interact with distinct cytoplasmic ef-
fectors (21) and activate different signaling pathways (22).
An attractive hypothesis is that only the phosphorylated
ITAM of Ig-a directly interacts with the SH2 domains of
syk and induce syk activation, whereas the activation of syk
through the Ig-b cytoplasmic tail is determined by the in-
teraction of another molecule. Whatever the intracellular
mechanism of syk activation through the two BCR sub-
units, our data clearly show that the overexpression of the
syk mutant differentially affects antigen presentation through
Ig-a and Ig-b. This is in agreement with previous data
showing that the mutation of Ig-b ITAM tyrosine residues
did not affect Ig-b–mediated antigen presentation (37),
whereas similar mutations in Ig-a ITAM only affected the
presentation of some, but not all, T cell epitopes (Table 1).
Therefore, there is compelling evidence that functionally
distinguishes classic and alternative pathways of antigen
presentation. Different peptides associate with recycling
and newly synthesized pools of class II molecules which are
specifically targeted by signals contained in the cytoplasmic
tails of antigen receptors. Although these signals are located
in a similar ITAM, they can be functionally distinguished.
Mutation of tyrosine residues in ITAM and overexpression
of the syk dominant negative mutant did not affect antigen
presentation using recycling class II molecules through the
Ig-b cytoplasmic tail, whereas both alter antigen presenta-
tion using newly synthesized class II through the Ig-a cyto-
plasmic tail. These data indicate that although both Ig-a–
and Ig-b–phosphorylated ITAMs activate syk, the kinase
domain of syk seems to be involved only in the targeting of
antigen receptors to newly synthesized class II molecules
which accumulated, before cell surface arrival, in endocytic
compartments called CIIV (for Class II vesicles [3]).
What is the function of the kinase domain of syk in
BCR-mediated antigen presentation? The phosphorylated
ITAMs of the Ig-a/Ig-b sheath interact and activate syk as
well as other cytoplasmic proteins (21). Recently, syk was
shown to associate with or to activate the regulatory sub-
unit of the phosphatidylinositol 3-kinase (PI3 kinase), p85
(41), which activates the catalytic subunit, p110 (42). The
target of this enzyme is the inositol ring bond to the fatty
acids constituting most cell membranes. The role of PI3 ki-
nases in intracellular transport has been demonstrated by
analysis of yeast mutants (vps 34, yeast equivalent of the PI3
kinase) deficient for transport to the vacuole (yeast equiva-
lent of lysosome), and by using wortmannin, inhibitor of
endosomal transport (42). The sequential recruitment of
syk and PI3 kinase, after receptor aggregation and ITAM
phosphorylation, could be a crucial step in endosomal sort-
ing of the BCR, as demonstrated previously for PTK re-
ceptors. The kinase domain of the epidermal growth factor
receptor (EGFR), is required in receptor sorting toward
multivesicular endosomal compartments (43). In the case of
the platelet growth factor receptor (PGFR), the sorting of
the receptor toward lysosomes is determined by the inter-
action of its kinase domain with PI3 kinase (44). Although
the precise mechanism by which syk kinase determines an-
tigen presentation remains unclear, our results allow us to
propose two nonexclusive hypotheses for syk kinase activ-
ity in endosomal sorting of antigen-bound BCR. Since the
syk dominant negative mutant specifically affected antigen
presentation using newly synthesized class II molecules, syk
might be required for the endosomal sorting of antigen-
bound BCR to class II compartments by the direct activa-
tion of the kinase domain of syk or by the recruitment of
cytoplasmic effectors, such as PI3 kinases. In a second
mechanism, the recruitment and activation of syk kinase
might alter the structure and composition of endosomal
compartments involved in antigen processing. In either
case, it appears likely that syk has a novel and important
function in intracellular trafficking and antigen presenta-
tion.
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